An Open Label, Single Session Study to Collect Tolerability Information Following Repeat Dosing of Darapladib in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2016
At a glance
- Drugs Darapladib (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 22 Jul 2009 Actual patient number (2) added as reported by ClinicalTrials.gov.
- 22 Jul 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 22 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.